Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Dermata Therapeutics ( (DRMA) ).
On May 14, 2025, Dermata Therapeutics received a notice from Nasdaq regarding non-compliance with the minimum bid price requirement, risking delisting. After requesting a hearing, the company was granted an exception until August 14, 2025, to meet the requirement. By August 22, 2025, Dermata regained compliance, closing the matter.
The most recent analyst rating on (DRMA) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Dermata Therapeutics stock, see the DRMA Stock Forecast page.
Spark’s Take on DRMA Stock
According to Spark, TipRanks’ AI Analyst, DRMA is a Underperform.
Dermata Therapeutics’ stock is primarily impacted by its financial health, characterized by significant operating losses and reliance on external financing. Technical analysis indicates a bearish trend with potential overselling, while valuation remains difficult to assess due to negative earnings. These factors contribute to a low overall score.
To see Spark’s full report on DRMA stock, click here.
More about Dermata Therapeutics
Dermata Therapeutics, Inc. operates in the biopharmaceutical industry, focusing on the development and commercialization of treatments for medical dermatology conditions.
Average Trading Volume: 17,536
Technical Sentiment Signal: Sell
Current Market Cap: $3.73M
For detailed information about DRMA stock, go to TipRanks’ Stock Analysis page.